From the Exam Room to the Formulary: Access Challenges in Adjunctive MDD Therapy

This episode, titled "From the Exam Room to the Formulary: Access Challenges in Adjunctive MDD Therapy," featured panelists discussing the following critical questions:

One in 6 patients with inadequate antidepressant response reports that poor efficacy and tolerability issues directly contribute to reduced medication adherence. How does tolerability factor into initial agent selection, and how do clinicians counsel patients on what to expect when starting adjunctive therapy?

From a managed care perspective, what are the structural barriers — such as prior authorization criteria, step therapy requirements, and formulary tier placement — that affect timely access to adjunctive antipsychotic therapy in major depressive disorder (MDD)?

What does the evidence say about the cost of delayed or inadequate treatment?

How are clinicians coordinating with office staff on insurance hurdles?

How should payers think about the total cost of care, including ER utilization, hospitalization, and lost productivity, when designing formulary access policies for adjunctive MDD therapies?

Led by the moderator, the expert mental health experts examined how tolerability shapes agent selection, with Wilkinson highlighting metabolic side effects and akathisia — most pronounced with aripiprazole — as key counseling points, alongside the value of anticipatory guidance in building patient trust and preventing premature discontinuation. Thase added that routine weight monitoring, though standard in internal medicine, has lagged in psychiatric practice and remains essential for catching metabolic side effects early, while both panelists noted that measurement-based care overall remains underutilized in psychiatry despite its demonstrated benefit to outcomes. Rhee and Bhide then turned to structural payer barriers, including prior authorization documentation requirements and non-preferred formulary tier placement, that can delay treatment and raise patient cost-sharing; Bhide cited data showing delayed or inadequate MDD treatment adds an estimated $9,000 to $11,000 per patient annually in direct costs, and noted that comorbid MDD often drives up costs for other conditions, such as diabetes and heart failure, in ways that aren't always attributed back to depression.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, "Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD," panelists continue their discussion on major depressive disorder and highlight the pivotal trial history and dose-finding evolution behind aripiprazole, along with quetiapine XR's distinct efficacy and tolerability profile and its implications for formulary positioning.